Postdilation of the WINGSPAN- Stent instead of predilation is feasible and safe Andreas Ragoschke-Schumm 1 , Stephanie Schindhelm 1 , Peter Schmidt 1 , Sascha Schiffler 1 , Andreas Hansch 1 , Robert Drescher 1 , Martin Bokemeyer 1 , Albrecht Günther 2 , Jens Weise 2 , Thomas E. Mayer 1 Friedrich-Schiller-University, Jena, Germany 1 Department of Neuroradiology, 2 Department of Neurology
Symptomatic intracranial stenoses Important cause of stroke, especially in blacks, Asians, and Hispanics. 10% in the white population 30% in the chinese population WASID trial: no benefit of warfarin over ASS but more complications ASS conventional therapy of choice Chimowitz et al. NEJM, 2005
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Postdilation of the WINGSPAN-Stent instead of predilation is
feasible and safe
Andreas Ragoschke-Schumm1, Stephanie Schindhelm1, Peter Schmidt1, Sascha Schiffler1, Andreas Hansch1, Robert Drescher1, Martin
Bokemeyer1, Albrecht Günther2, Jens Weise2, Thomas E. Mayer1 Friedrich-Schiller-University, Jena, Germany
1Department of Neuroradiology, 2Department of Neurology
Symptomatic intracranial stenoses
• Important cause of stroke, especially in blacks, Asians, and Hispanics. – 10% in the white population– 30% in the chinese population
• WASID trial: no benefit of warfarin over ASS but more complications ASS conventional therapy of choice
Chimowitz et al. NEJM, 2005
Chimowitz et al. NEJM, 2005
Risk of stroke recurrence
• Subgroup analyses from WASID: 1 year risk
– Stenoses 70-99 % 18 %– Stenoses 70-99 % and qualifying event within
30 d before study enrollment 23%!
Risk of stroke recurrence
Kasner et al. Circulation, 2006Kasner et al. Neurology, 2006
Need for more effective Treatment!
One Approach:Intracranial PTA and stenting
WINGSPAN-Stent
• Self expanding Nitinol-Stent, Over-The-Wire• Indication: symptomatic intracranial stenoses• Diameter: 2.5 mm – 4.5 mm, length 9, 15, 20 mm
According to manufacturer and
WINGSPAN-Study
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
Problem• Predilation poses potential risk of unprotected dissection, vessel occlusion or vessel
rupture
• There are cases where stenting alone could lead to sufficcient treatment of the stenosis
Questions
• Does primary Stent-deployment help avoid dilation at all?
• Does postdilation harm the stent or the patient?
According to our
modification
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
WINGSPAN-Stentmode of deployment
Study
• Retrospective• All Patients that were treated with wingspan stents were
assessed for technical success• All Patients treated for symptomatic intracranial stenoses
were assessed for treatment assocciated complications, periprocedural outcome and restenoses.
• Indication: interdisciplinary with a neurologist• Postprocedural follow-up (DSA after 6 months,
Doppler/Duplex-Sonography and neurological examination every 3 months during the first year.
results
• Observation time 02/2008 - 09/2010• 34 Patients (25 m, 9 f), Wingspan N=40• 24 patients were treated with subacute
symptomatic stenoses (>24 hrs.)• 9 with acute vessel occlusion (all
vertebrobasilar)• 1 with acute aneurysmal SAH (dissection during
endovascular embolisation)
Subacute intracranial stenoses
• Average stenosis rate 75% (55%-99%)• Age: average 60.7 yrs, (ranging from 43 to